AllSci News
Tarsus bets USD 565 million to displace Betadine in intravitreal injection prep
Irvine, California-based Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has acquired iRenix Medical, Inc., a privately held clinical-stage ophthalmic...
FDA grants fast-track status to Arialys’ first-in-class anti-NMDA receptor encephalitis therapy
La Jolla-based Arialys Therapeutics announced receipt of US FDA Fast Track Designation for ART5803, a humanized monovalent monoclonal antibody designed to block…
Sanofi’s Sarclisa Escena becomes first anticancer drug approved for on-body injector delivery
Sanofi has received US FDA approval for Sarclisa Escena (isatuximab-irfc), a subcutaneous formulation of its anti-CD38 antibody delivered via an automated on-body…
Rani secures PegBio as client for oral delivery platform to advance metabolic disease pipeline
China-based PegBio Co., Ltd. (HKEX: 2565) and San Jose, California-based Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) announced a research and development collaboration…
Leads Biolabs wins NMPA priority review for first-ever EP-NEC treatment opamtistomig
China-based Nanjing Leads Biolabs Co., Ltd. (HKEX: 09887) announced that China’s National Medical Products Administration (NMPA) has accepted its biologics license application…
LEO Pharma extends Adtralza into younger children with positive pediatric safety data
Denmark-based LEO Pharma A/S has reported positive results from the Phase II TRAPEDS-1 trial, a pediatric study evaluating tralokinumab (Adbry/Adtralza) in...
Cue Bio secures USD 50m to advance autoimmune pipeline after three-fold valuation jump
Boston-based Cue Biopharma, Inc. (Nasdaq: CUE) announced a USD 50 million private placement to fund clinical development across its immunological disorders...
Hansoh's B7-H3 antibody-drug conjugate achieves first-ever Phase III overall survival win in small-cell lung cancer
Hansoh Pharma's ARTEMIS-008 has delivered what the field has not seen before: the first Phase III overall survival benefit for a B7-H3-targeted...
Bayer raises EUR 3.0 billion by selling minority stake in contraceptives unit
Bayer (ETR: BAYN) has secured €3.0 billion in equity capital from Apollo Global Management (NYSE: APO) through a minority stake in a newly established...
MindRank's USD 52m Series B advances AI-designed GLP-1 into pivotal Phase III obesity trial
China-based MindRank AI Ltd. has closed a USD 52 million Series B financing round to advance its AI-native drug discovery platform and clinical pipeline,...
Bausch + Lomb's glaucoma neuroprotective candidate fails Phase II primary endpoint
Bausch + Lomb's BL1107 glaucoma Phase II trial failed to replicate earlier visual function signals in primary open-angle glaucoma, a setback that closes the...
Apertura partners with NIH on TfR1 capsid approach for Niemann-Pick gene therapy
New York-based Apertura Gene Therapy has entered a Cooperative Research and Development Agreement with two NIH institutes to advance preclinical...
Roche discontinues huntingtin-targeting antisense programs tominersen and RG6496 in Huntington's disease
Roche has announced the discontinuation of two Huntington's disease programs simultaneously: the Phase II GENERATION HD2 study of tominersen (RG6042), a...
FDA pauses CRL publication while HHS develops formal disclosure rule
Category: Regulatory Policy | Regulatory Body: FDA | Geography: United States | Instrument: Rule/Rulemaking
JAX joins Broad-led consortium on USD 34.5 million ARPA-H rare disease gene-editing award
The Jackson Laboratory (JAX), in collaboration with the Broad Institute and partners across 12 institutions, has been selected for an up to USD 34.5 million...
The AllSci Brief
Free, systematic R&D and deal news. Daily.